ClinicalTrials.gg
CompletedNCT02904902Updated May 12, 2020Results posted

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

A Phase 3 interventional study of adalimumab in Hidradenitis Suppurativa, sponsored by AbbVie. Completed at 8 sites in Japan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-05-12.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.

Enrollment
11th of 11
15 · median 243
Started
2016
with 4 others
Phase 3
6 of 18
none open now
Registered
8th of 18
by date

Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2016, is one of 6 in phase 3, and was the 8th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hidradenitis Suppurativa by AbbVie, or all of them as a file.
02

Study summary

This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).

Read the detailed description

Prior to initiation of this study, global Phase 2b study and pivotal Phase III studies were completed in the Western countries and market authorization of adalimumab was approved in United States (US) and European Union (EU) for the treatment of subjects with HS. The differences between this study and global studies include sample size, study design, duration, and race.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • efficacy
  • safety
  • adalimumab
  • japanese participants
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have a diagnosis of HS;
  • Participant must have any HS symptom at least 6 months prior to Baseline;
  • HS lesions must be present in at least 2 distinct anatomic areas, one of which must be Hurley Stage II or Hurley Stage III;
  • Participant must have stable HS for at least 2 months (60 days) prior to Screening and also at the Baseline visit;
  • Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with adalimumab or other anti-tumor necrosis factor (TNF) therapy or participation in adalimumab trial;
  • Any other active skin lesion or condition that may interfere with assessment of HS;
  • Participants received antibiotic treatment for HS within 28 days prior to the Baseline visit other than those allowed per protocol. Participant on permitted oral antibiotic treatment (doxycycline or minocycline only) for HS who have not been on a stable dose for at least 28 days prior to the Baseline visit;
  • Participants received prescription topical therapies for the treatment for HS within 14 days prior to the Baseline visit;
  • Participants received systemic non-biologic therapies with potential therapeutic impact for HS less than 28 days prior to the Baseline visit;
  • Participants received oral concomitant analgesics (non-opioids and opioids) for HS-related pain within 14 days prior to the Baseline visit.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).

    Drug: adalimumab

Interventions

  • Subcutaneous Injection

    Also known as: Humira

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

    HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving AN Count of 0, 1, or 2 at Week 12

    The percentage of participants with AN counts lowered to 0, 1, or 2 at Week 12.

    Time frame: Week 12

  2. Percentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=3

    The participant's Global Assessment of Skin Pain NRS was used to assess the worst skin pain due to HS. Scores range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours."

    Time frame: Week 0 (Baseline), Week 2

  3. Change From Baseline to Week 12 in Modified Sartorius Scale Score

    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.

    Time frame: Baseline (last non-missing value on or before the date of first dose of study drug), Week 2, Week 4, Week 8, Week 12

07

Results

Posted Feb 27, 2019

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started15
Completed14
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
percentage of participantsAdalimumab
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 1286.7 (59.5 to 98.3)
SecondaryPercentage of Participants Achieving AN Count of 0, 1, or 2 at Week 12

The percentage of participants with AN counts lowered to 0, 1, or 2 at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving AN Count of 0, 1, or 2 at Week 12
percentage of participantsAdalimumab
Percentage of Participants Achieving AN Count of 0, 1, or 2 at Week 1273.3 (44.9 to 92.2)
SecondaryPercentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=3

The participant's Global Assessment of Skin Pain NRS was used to assess the worst skin pain due to HS. Scores range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours."

Time frame:
Week 0 (Baseline), Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=3
percentage of participantsAdalimumab
Percentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=333.3 (7.5 to 70.1)
SecondaryChange From Baseline to Week 12 in Modified Sartorius Scale Score

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.

Time frame:
Baseline (last non-missing value on or before the date of first dose of study drug), Week 2, Week 4, Week 8, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in Modified Sartorius Scale Score
units on a scaleAdalimumab
Week 2-16.7 ± 15.06
Week 4-38.7 ± 31.46
Week 8-49.9 ± 48.10
Week 12-61.4 ± 45.05

Adverse events

Collected over From first dose of study drug through 70 days after the last dose of study drug. The mean duration of adalimumab exposure was 717.5 days (median 742.0 days, range 112 - 883 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab0/15 (0%)5/15 (33.3%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
CellulitisInfections and infestations2/15
Subcutaneous abscessInfections and infestations1/15
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/15
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/15
Deep vein thrombosisVascular disorders1/15
Most frequent other events
Showing 10 of 52
Most frequent other events
EventAdalimumab
InfluenzaInfections and infestations6/15
NasopharyngitisInfections and infestations5/15
PeriodontitisInfections and infestations4/15
ConstipationGastrointestinal disorders2/15
Dental cariesGastrointestinal disorders2/15
DiarrhoeaGastrointestinal disorders2/15
ToothacheGastrointestinal disorders2/15
PyrexiaGeneral disorders2/15
SwellingGeneral disorders2/15
Pulpitis dentalInfections and infestations2/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Adalimumab
Mean42.1 ± 6.94
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female2
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adalimumab
Hispanic or Latino0
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adalimumab
American Indian or Alaska Native0
Asian15
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Modified Sartorius Scale
Modified Sartorius Scale(units on a scale)Adalimumab
Mean137.3 ± 59.21
08

Study locations

8 sites
  • Nagoya City University Hospital /ID# 151495
    Nagoya-shi, Aichi 467-8602, Japan
  • Kurume University Hospital /ID# 152579
    Kurume-shi, Fukuoka 830-0011, Japan
  • Takagi Dermatological Clinic /ID# 151906
    Obihiro, Hokkaido 080-0013, Japan
  • University of the Ryukyus Hosp /ID# 152268
    Nakagami-gun, Okinawa 903-0215, Japan
  • NHO Osaka National Hosp /ID# 152452
    Osaka-shi, Osaka 540-0006, Japan
  • Tokai University Hachioji Hosp /ID# 151338
    Hachioji, Tokyo 〒192-0032, Japan
  • Tokyo Medical University Hospital /ID# 154171
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Fukuoka University Hospital /ID# 151350
    Fukuoka, 814-0180, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Sep 2017, 11 months.

Results were first posted in Feb 2019, 1 year 5 months after primary completion.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Sep 19, 2016
StartActual
Sep 6, 2016
Primary completionActual
Sep 1, 2017
CompletionActual
May 30, 2019
Results first posted
Feb 27, 2019
Last update
May 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02904902
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 19, 2016
Start date
Sep 6, 2016
Primary completion
Sep 1, 2017
Completion
May 30, 2019
Results posted
Feb 27, 2019
Last update
May 12, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion